Navigation Links
Phase II Clinical Trial Results Encouraging for PA-Based Women's Health Company
Date:1/11/2011

WAYNE, Pa., Jan. 11, 2011 /PRNewswire/ -- FemmePharma Global Healthcare, a privately held women's health company dedicated to improving the quality of life for women, today announces completion of its Phase II clinical dose ranging/safety trial with FP 1097 in women suffering from urinary incontinence or overactive bladder (OAB).

The Phase II FP 1097 trial demonstrated that drug can be delivered to the bladder via intra-vaginal administration successfully. The clinical trial showed a statistically significant 25 percent reduction of micturitions and a 75 percent reduction of incontinence episodes. Treatment-related adverse events were low with no serious adverse events and all subjects completing the trial. Over 50 percent of the patients on FP 1097 achieved total continence.

Based on the results, FemmePharma Global Healthcare was granted permission to proceed to a pivotal Phase III trial by the Food and Drug Administration (FDA). In addition the FDA will grant FemmePharma 505B1 filing status for FP 1097.

According to published reports, it is estimated that more than 30 million Americans (mostly women) experience OAB. IMS Healthcare estimates that the OAB prescription market in the United States exceeds $2.0 billion annually while the total worldwide market including drugs, diapers and devices exceeds $7.0 billion annually.

"The encouraging safety and efficacy results from this randomized study of FP 1097 provides a basis to advance this innovative product into Phase III clinical development," said Gerianne DiPiano, founder, President and CEO of FemmePharma Global Healthcare, Inc.


'/>"/>
SOURCE FemmePharma Global Healthcare
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy
2. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
3. MacroGenics Initiates Phase I Clinical Trial of MGAH22 for Patients With HER2-Expressing Solid Tumors
4. Juventas Therapeutics Initiating Phase II Clinical Trial of JVS-100 for Treatment of Critical Limb Ischemia
5. Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer
6. Spherix Phase 2 Trial with D-tagatose Determines Minimum Dose for HbA1c and Triglycerides
7. GeNO LLC Initiates Phase 2 Trial For Nitric Oxide Delivery System
8. Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study
9. YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387
10. Early Safety Results Promising for Phase I/II Trial of Gene Therapy Treatment of Hemophilia B
11. Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... (PRWEB) December 23, 2014 GMO corn ... biotechnology company, Syngenta, are in the process of being ... The consolidated case is In Re: Syngenta AG MIR ... District Court for the District of Kansas. , Management ... been handed over to U.S. District Judge John W. ...
(Date:12/24/2014)... 2014 SoundConnect’s ... to introduce cutting edge communication technology, provide ... of platform upgrades. This webinar series demonstrates ... in their quest to leverage web conferencing’s ... to SoundConnect’s Marketing Manager, Seanna Baumgartner, “Our ...
(Date:12/24/2014)... 2014 According to Ross Selinger, President of ... ITRA Global, the national office market continues to be strong, ... is evidenced by the third quarter’s surprising 3.9% GDP, unemployment ... energy costs have held inflation down and the Fed is ... housing market remaining soft. , This solid economic news is ...
(Date:12/24/2014)... Nashville Fertility Center announced that Dr. ... American Society for Reproductive Medicine (ASRM), a leading professional ... medicine. In his new role as treasurer, Dr. ... and will have a voice in furthering the mission ... ASRM since 1984 when he joined while conducting fellowship ...
Breaking Biology Technology:Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3
... - Strong Sales Growth Across All Product Lines ... Sales Growth ... IRVINE, Calif., April 22 Edwards Lifesciences,Corporation (NYSE: EW ... disease, today reported net income for the,quarter ended March 31, 2008 ...
... Trust, Inc.,(NYSE: BMR ) today announced that ... additional shares of common stock in,connection with BioMed,s ... 2008. In total, the company sold 6,129,000 shares ... $156.3,million., The underwriters for the offering are ...
... Calif., April 22 Microchip Biotechnologies,Inc. (MBI) ... multi-patent license,agreement with GE Healthcare that significantly ... of lab-on-a-chip devices. The,patents cover design and ... "Licensing these fundamental patents continues to build ...
Cached Biology Technology:Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 2Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 3Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 4Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 5Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 6Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 7Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 8Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 9Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 10Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 11Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 12Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 13Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 14BioMed Realty Trust Announces Exercise of Over-Allotment Option for Common Stock 2BioMed Realty Trust Announces Exercise of Over-Allotment Option for Common Stock 3Microchip Biotechnologies, Inc. Enters Into License Arrangement With GE Healthcare for Fundamental Microfluidic Patents 2
(Date:12/17/2014)... 2014 Research and Markets ( ... "Samsung Galaxy S5 - Home Button Synaptics ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... technology than the iPhone 5S, Samsung introduces for ... product. The Galaxy S5 home button ...
(Date:12/17/2014)... NEW YORK , Dec. 15, 2014 /PRNewswire-USNewswire/ ... a Good Clinical Practices (GCP) audit to confirm ... Administration (FDA) regulations. This accomplishment enables HITLAB to ... trials utilizing the highest principles for patient safety ... to improve global healthcare access, quality, and delivery ...
(Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) ... Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this ... in biomedical applications. Chemical sensors help in recording ... during surgical procedures. The Global Chemical Sensor market ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... Such Board on the Market, Stantum,s SMK Series ... Own Resistive Multi-Touch Applications, SAN DIEGO, Sept. ... developer of multi-touch sensing,technology, today introduced a demo, ... resistive multi-touch technology, which lets,users simultaneously move an ...
... been awarded $1 million from the US Department of ... conversion technologies. The grant is one of six awarded ... their advanced biofuels projects. In total, the DOE will ... for their research into how non-food feedstocks can be ...
... skin disorder called vitiligo, which causes unsightly white patches on ... A Loyola University Hospital researcher has won a five-year, $1.7 ... vitiligo. This research also could point the way to new ... Vitiligo appears to be an auto-immune disease, in which the ...
Cached Biology News:Stantum Offering Demo, Evaluation & Development Board Based on Its Patented Resistive Multi-Touch Technology 2Stevens awarded $1M for advanced biofuels research 2Vitiligo skin disorder could yield clues in fight against melanoma 2
Intestinal Epithelium Differentiation Environment...
... provides a familiar interface for data ... warehousing. The transition from paper to ... LABTrack contains an integrated LIMS, ... rules mechanism. These functions allow LABTrack ...
Mouse monoclonal [M2II-12] to MRP2 ( Abpromise for all tested applications). entrezGeneID: 1244 SwissProtID: Q92887...
Rab GDP dissociation inhibitor beta...
Biology Products: